Granulocyte colony-stimulating factor-associated aortitis in a woman with breast cancer: a case report

Nana Matsumoto1, Naoto Kondo2*, Yumi Wanifuchi-Endo2, Tomoko Asano2, Tomoka Hisada2, Yasuaki Uemoto2, Akiko Kato2, Mitsuo Terada2, Natsumi Yamanaka2, Ayaka Isogai2, Muneyuki Takayama1, Takeshi Hasegawa1, Koichi Ito1, Keiji Mashita1 and Tatsuya Toyama2

Abstract

Background: Granulocyte colony-stimulating factor (G-CSF) is increasingly used to prevent chemotherapy-associated febrile neutropenia. Generally, aortitis is not considered a side effect of G-CSF and is thought to be extremely rare. Aortitis is an inflammation of the aorta and occurs mainly in connective tissue diseases (Takayasu arteritis, giant cell arteritis, etc.) and infectious diseases (bacterial endocarditis, syphilis, etc.). We report herein a rare case of G-CSF associated with aortitis in a woman with breast cancer.

Case presentation: Here, we present a case involving a 63-year-old woman with luminal type stage IIa breast cancer. The patient’s treatment was initiated with docetaxel and cyclophosphamide, with pegfilgrastim (PEG-G) as support. After PEG-G administration on day 3, the patient developed an intermittent fever of up to 39.4 °C on day 10 and visited our outpatient clinic on day 13 with persistent high fever. Laboratory tests revealed a high neutrophil count (14,000/μL) and a high C-reactive protein (CRP) level (42.8 mg/dL) without any other abnormalities. Contrast-enhanced computed tomography scanning revealed soft tissue thickening with weak enhancement around the wall of the thoraco-abdominal aorta, aortic arch and left subclavian artery. The patient did not respond to antimicrobial agents. On the basis of these observations, the patient was diagnosed with PEG-G-induced aortitis, and her condition rapidly improved without corticosteroids.

Conclusions: Clinicians should be aware of aortitis as a potential complication in patients undergoing G-CSF chemotherapy. In cases with persistent high fever after PEG-G administration, and in the absence of infection, aortitis should be suspected.

Keywords: Granulocyte colony-stimulating factor (G-CSF), Aortitis, Breast cancer, Pegfilgrastim

Background

Pegfilgrastim (PEG-G) is a long-acting granulocyte colony-stimulating factor (G-CSF) widely used to prevent chemotherapy-associated febrile neutropenia in cancer patients. G-CSF preparations bind to G-CSF receptors on neutrophil progenitor cells in the bone marrow, promoting their differentiation into neutrophils. The most common adverse effects of G-CSF are bone pain and injection-site reactions, although generally less serious adverse events have been reported [1]. According to the Japanese Adverse Drug Event Report (JADER) by the Pharmaceuticals and Medical Devices Agency (PMDA), aortitis is an adverse effect of G-CSF, although this has rarely been reported [2]. Here, we report a rare case of...
PEG-G-induced aortic inflammation in a patient receiving post-operative chemotherapy for early breast cancer.

**Case presentation**

The case involved a 62-year-old postmenopausal woman without any personal or family medical history. The patient underwent a left mastectomy and sentinel lymph node biopsy for left breast cancer. A pathological examination revealed the following: invasive ductal carcinoma, pT2 (22 mm), nuclear grade 3, pN0, estrogen receptor (ER) and progesterone receptor (PgR) positive, human epidermal growth factor receptor 2 (HER2) negative, and pT2N0M0 stage IIa.

On day 1, the patient was administered a chemotherapy regimen consisting of docetaxel (75 mg/m²) and cyclophosphamide (600 mg/m²), together with dexamethasone (6.8 mg). The patient was administered oral dexamethasone (8 mg) on days 2–4 and subcutaneous PEG-G on day 3. On day 10 (day 8 after PEG-G administration), the patient complained of intermittent high fever (up to 39.4 °C); the fever persisted even after the administration of levofloxacin (LVFX), which was prescribed for febrile neutropenia. In addition to fever, the patient developed other symptoms, including loss of appetite and shortness of breath, and visited our hospital on day 13 (11 days after PEG-G administration). At admission, the patient’s body temperature was 39.2 °C. Laboratory examination revealed a high neutrophil count (14,000/µL) and elevated CRP (42.78 mg/dL) without any other abnormalities. The erythrocyte sedimentation rate was 76 mm/h. The levels of anti-nuclear antibody (ANA), myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA), serine proteinase 3 anti-neutrophil cytoplasmic antibody (PR3-ANCA), and rheumatoid factor were within normal limits. To rule out viral infections, we performed an antibody test for human T-cell lymphocytis reported in recent years are listed in Table 3 [6–13].

Contrast-enhanced computed tomography (CT) scan on pre-operation showed no abnormalities around the aorta (Fig. 1a–c). At the time of admission, CT scanning revealed soft tissue thickening with weak enhancement around the wall of the thoraco-abdominal aorta, aortic arch and left subclavian artery (Fig. 1d–f). From the patient’s clinical course and imaging data, we suspected G-CSF-associated aortitis. At that point, we could not rule out infection because we had no results of autoimmune diseases because all ANA, MPO-ANCA, and PR3-ANCA values were within normal ranges. Since viral antibody tests were also negative and no bacterial growth was observed in blood and urine cultures, we concluded that G-CSF was the most suspicious cause of this aortitis.

Corticosteroids are commonly used to treat patients with suspected autoimmune diseases, such as Takayasu arteritis (TAK). However, there is no established treatment for G-CSF-associated aortitis. In general, G-CSF-associated aortitis has good prognosis and often resolves spontaneously without the administration of corticosteroids [6]. Moreover, previous reports show that there is no difference in the therapeutic effect and the time to remission of G-CSF-associated aortitis with or without corticosteroids [7]. The cases of G-CSF-associated aortitis reported in recent years are listed in Table 3 [6–13].

| Blood cell count | Normal values |
|------------------|---------------|
| White blood cells (µL) | 15,600 | 3000–9000 |
| Neutrophils (%) | 90.0 | 40.0–69.0 |
| Eosinophils (%) | 0 | 0–5.0 |
| Basophil (%) | 6.0 | 0–2.0 |
| Lymphocytes (%) | 30.0 | 26.0–46.0 |
| Red blood cells (µL) | 3.54 × 10⁶ | 3.53 × 10⁶–5.25 × 10⁶ |
| Hemoglobin (g/dL) | 10.5 | 10.6–16.5 |
| Platelet count (µL) | 22.5 × 10³ | 13.8 × 10³–30.9 × 10³ |
| CRP (mg/dL) | 42.8 | ≤ 0.3 |
Aortitis caused by PEG-G tended to develop within 2 weeks of G-CSF administration and to resolve spontaneously within 3 weeks, as in the present case. We hypothesized that this common period of time was due to the duration of action of PEG-G, and that once the effects of PEG-G wore off, the aortitis would spontaneously abate. What is also interesting about this case is that despite the extensive lesions, the disease resolved quickly and spontaneously without corticosteroid treatment. This suggests that the extent of the lesions is not related to the need for corticosteroid treatment. On the other hand, it has been reported that G-CSF-associated aortitis lasting more than 3 weeks was relieved by corticosteroid administration, and we believe that corticosteroids should be considered in cases of long-term lack of improvement.

Although there are reports of G-CSF re-administration after symptom improvement in patients with G-CSF-associated aortitis, caution is required because some patients had recurrent aortitis [6, 14]. In this case, at the patient’s request, we shifted to endocrine therapy without re-administering PEG-G, and aortitis recurrence was not observed for 15 months after the onset of symptoms.

In breast cancer patients, dose-dense chemotherapy involving more frequent administration of chemotherapy...
agents than in standard chemotherapy significantly improved clinical outcomes [15, 16]. The addition of G-CSF to chemotherapy regimens to prevent chemotherapy-induced febrile neutropenia yields favorable clinical outcomes in breast cancer patients [17, 18]. Therefore, physicians should be aware that because most breast cancer patients undergo chemotherapy with PEG-G, aortitis may easily develop.

**Conclusion**

Clinicians should be aware of aortitis as a possible complication in patients undergoing chemotherapy with G-CSF. In cases with persistently high fever after G-CSF administration, aortitis should be suspected and a thoraco-abdominal CT scan or scintigraphy should be performed at an early stage.

**Table 3**  Reported cases of G-CSF-associated aortitis in recent years

| References | Age G-CSF | Period* | Location of aortitis | Steroid treatment | Re-administration of G-CSF |
|------------|-----------|---------|----------------------|-------------------|---------------------------|
| [6]        | 65 PEG-G  | 8–18    | Aortic arch          | None              | Re-administered and aortitis recurred |
| [7]        | 72 PEG —G | 4–14    | Thoracic             | None              | None                      |
| [8]        | 52 Details unknown | 14–38 | Aortic arch and abdominal | Prednisolone 50 mg  | None                      |
| [9]        | 58 PEG -G  | 8–21    | Right subclavian     | None              | None                      |
| [10]       | 43 PEG-G   | 8–36    | Aortic arch          | Prednisolone 60 mg | None                      |
| [11]       | 77 Details unknown | 8–21 | Bilateral common carotid and left subclavian | None              | None                      |
| [12]       | 61 PEG-G   | 7–17    | Thoracic             | None              | None                      |
| [13]       | 60 Details unknown | 5–15 | Thoraco-abdominal     | Prednisolone 60 mg | None                      |
| [13]       | 70 Filgrastim | 15–25 | Thoraco-abdominal     | Prednisolone 60 mg | None                      |
| Present case | 62 PEG -G  | 7–17    | Thoraco-abdominal, aortic arch and left subclavian | None              | None                      |

PEG-G: pegfilgrastim
* Days with fever from G-CSF administration

**Abbreviations**

G-CSF: Granulocyte colony-stimulating factor; PEG-G: Pegfilgrastim; CRP: C-reactive protein; JADER: Japanese Adverse Drug Event Report; PMDA: Pharmaceuticals and Medical Devices Agency; ER: Estrogen receptor; PgR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2; LVFX: Levofloxacin; ANA: Anti-nuclear antibody; MPO-ANCA: Myeloperoxidase anti-neutrophil cytoplasmic antibody; PR3-ANCA: Serine proteinase 3 anti-neutrophil cytoplasmic antibody; TAK: Takayasu arteritis.

**Acknowledgements**

We thank F. Kobia, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

**Author contributions**

NM wrote the manuscript. NK contributed to the treatment of the patient and revised the manuscript. AI, NY, AK, MT, YU, TH, TA, and YW-E participated in patient treatment. TT treated the patients and supervised the study. All authors read and approved the final manuscript.

**Funding**

No funding was received for this study.

**Availability of data and materials**

All data underlying this report are included within the article.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

The patient gave written informed consent for publication of this case report.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Surgery, Inazawa Kosei Hospital, 7 Zichono, Sobuechohonko, Inazawa 495-8531, Japan. 2Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasaki, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

**Received:** 25 March 2022   **Accepted:** 12 August 2022

**Published online:** 18 August 2022

**References**

1. Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Honebeiner M. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev. 2012;10:CD007913.
2. Oshima Y, Takahashi S, Tani K, Tojo A. Granulocyte colony-stimulating factor-associated aortitis in the Japanese adverse drug event report database. Cytokine. 2019;119:47–51.
3. Cuchacovich R. Immunopathogenesis of vasculitis. Curr Rheumatol Rep. 2002;49–17.
4. Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002;17:413–23.
5. Bossone E, Pluchinotta FR, Andreas M, Blanc P, Citro R, Limongelli G, et al. Aortitis. Vasc Pharmacol. 2016;80:1–10.
6. Harada M, Motoki H, Sakai T, Kuwahara K. Granulocyte colony stimulating factor-associated aortitis evaluated via multiple imaging modalities including vascular echography: a case report. Eur Soc Cardiol. 2020. https://doi.org/10.1093/ehjcr/ytaa503.
7. Shirai T, Komatsu H, Sato H, Fujii H, Ishii T, Harigae H. Migratory aortitis associated with granulocyte-colony-stimulating factor. Intern Med. 2020;59:1539–63.
8. Hoshina H, Takei H. Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature. BMC Cancer. 2019;19:1217. https://doi.org/10.1186/s12885-019-6403-9.
9. Jimbo H, et al. Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report. Surg Case Rep. 2021;7:197.
10. Koyama Y, et al. Successful treatment of G-CSF-related aortitis with prednisolone during preoperative chemotherapy for breast cancer: a case report. Surg Case Rep. 2021;7:23.
11. Kinjo Y, et al. Acute arteritis after G-CSF administration. Int Cancer Conf J. 2019;8:77–80.
12. Chino T, et al. A Case of arteritis that developed after pegfilgrastim administration during chemotherapy for breast cancer. Jpn J Cancer Chemother. 2018;45(12):1771–4.
13. Parodis I, et al. G-CSF-induced aortitis: two cases and review of the literature. Autoimmun Rev. 2019;18(6):615–20.
14. Mukai T, Kubo S, Morita Y, Yamamoto M, Ikeda M. Aortitis which developed after the administration of granulocyte-colony stimulating factor. Modern Rheumatol Case Rep. 2020;4:74–8.
15. Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/ cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21:1431–9.
16. Kimmel S, et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer. 2006;94:2337–44.
17. Vogel CL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–84.
18. Holmes FA, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727–31.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.